Skip to main content
logo
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.720
-0.060 (-3.37%)
Sep 15, 2026, 4:00 PM EDT - Market closed

Allogene Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.64-0.020.10.16114.09
Revenue Growth
---76.84%-39.10%-99.86%-
Gross Profit
-117.88-150.15-192.28-242.82-256.23-106.09
Operating Income
-180.32-206.93-257.48-314.49-335.54-180.19
Net Income
-165.49-190.89-257.59-327.27-340.41-182.05
Earnings Per Share
-0.65-0.87-1.32-2.09-2.38-1.34
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
332.6250.21292.48448.7517.32457.3
Total Debt
79.0183.2590.7695.12101.1273.13
Net Cash (Debt)
253.6166.96201.72353.58416.2384.17
Net Cash Growth
36.25%-17.23%-42.95%-15.05%8.34%-50.37%
Net Cash Per Share
1.000.761.042.252.912.83

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-102.2-149.25-200.3-237.73-220.52-184.81
Capital Expenditures
-0.4-0.39-0.69-1.52-5.19-21.45
Free Cash Flow
-102.6-149.63-200.99-239.25-225.71-206.26
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------92.99%
Operating Margin
-3886.14%--1170372.73%-331044.21%-215087.18%-157.94%
Pretax Margin
-3566.68%--1168850.00%-344489.47%-218214.10%-159.57%
Profit Margin
-3566.68%--1170863.64%-344489.47%-218214.10%-159.57%
FCF Margin
-2211.16%--913609.09%-251841.05%-144685.90%-180.79%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
128.07-20300.075685.985814.6318.64